Insider · SEC Form 4 filer
John Schmid
Past buys: 4 of 5 beat
Companies
Where they file as an insider
BlossomHill Therapeutics (BLSM) Director Latest filing Aug 10, 2026
Anaptysbio (ANAB) Director Latest filing Jun 15, 2026
First Tracks Biotherapeutics (TRAX) Director Latest filing Jun 15, 2026
BridgeBio Oncology Therapeutics (BBOT) Insider Latest filing Aug 11, 2025
Poseida Therapeutics (PSTX) Director Latest filing Jan 8, 2025
Xeris Biopharma (XERS) Director Latest filing Aug 12, 2024
Design Therapeutics (DSGN) Director Latest filing Mar 25, 2024
Track record
Did their buys beat the typical stock?
Open-market buys8
Quarters checked 6 months later5
Beat the typical stock 4 of 5
Quarters too new to check1
4 of 5 checked quarters beat the typical stock. A past record is data, not a forecast.
BlossomHill Therapeutics (BLSM) Bought Aug 10, 2026 · $96K · 6,000 shares Too new Too new. Its 6-month check uses prices as of Mar 31, 2027.
Xeris Biopharma (XERS) Bought Aug 9–12, 2024 · $20.3K · 8,800 shares Beat typical Sep 30, 2024 $2.85 → Mar 31, 2025 $5.49 · +92.6% (typical stock −7.5%)
Xeris Biopharma (XERS) Bought May 10, 2024 · $10.3K · 5,400 shares Beat typical Jun 30, 2024 $2.25 → Dec 31, 2024 $3.39 · +50.7% (typical stock +3.9%)
Design Therapeutics (DSGN) Bought Mar 22–25, 2024 · $99.8K · 26,965 shares Beat typical Mar 31, 2024 $4.03 → Sep 30, 2024 $5.38 · +33.5% (typical stock +3.2%)
Xeris Biopharma (XERS) Bought Mar 14, 2024 · $9.72K · 4,500 shares Beat typical Mar 31, 2024 $2.21 → Sep 30, 2024 $2.85 · +29.0% (typical stock +3.2%)
Xeris Biopharma (XERS) Bought Nov 16, 2023 · $9.81K · 6,500 shares Behind typical Dec 31, 2023 $2.35 → Jun 30, 2024 $2.25 · −4.3% (typical stock −1.2%)
Each row is one stock in one quarter, however many buys it took. We take the stock's price at the end of that quarter and again 6 months later, and compare it with the typical stock over the same dates. Prices are quarter-end values from funds' 13F reports (the middle value across 3 or more funds), through Sep 30, 2026. Moves past 3 times up or down, mostly stock splits, are left out. How we tested this.
Past results. This is data, not advice.
Free weekly email
Each week's biggest real insider buys, cluster buys and fund moves, every one dated. One email a week. Unsubscribe in one click.